Mitral regurgitation accounted for 65% of all mitral valve diseases, including primary mitral regurgitation and secondary mitral regurgitation. It was evaluated according to jet area, regurgitation volume and other indicators
Mitral valve disease: heart valve disease with the highest prevalence. Mitral valve diseases mainly include mitral regurgitation, mitral stenosis and mitral valve prolapse. Mitral regurgitation accounts for 65%, which is mainly due to mitral valve lesions caused by mitral leaflets, valve rings, papillary muscles and tendons, resulting in lax closure of the mitral valve during cardiac contraction, and blood flows from the left ventricle into the left atrium
Mitral regurgitation is identified by symptoms, clinical evidence and transesophageal echocardiography (TTE). It is usually divided into two types: primary mitral regurgitation (DMR) and secondary mitral regurgitation (fMR). The degree of mitral regurgitation is confirmed according to jet area, reflux volume and other indicators, and then treated by traditional drug treatment, surgery or transcatheter intervention
TMV treatment does not require thoracotomy, cardiopulmonary bypass and cardiac arrest. Trauma, bleeding volume and pain degree of patients in recovery stage are also the lowest of the three methods. It is suitable for patients with high-risk surgery and single membrane valve disease
TMV treatment does not involve thoracotomy, cardiopulmonary bypass and cardiac arrest; Trauma, blood loss and patient pain are also the lightest. However, the effect of surgery is not as good as surgery in some aspects, and it is not suitable for patients with multi membranous flap and combined lesions
The penetration rates of transcatheter mitral valve intervention in China and the United States are 1% and 2% respectively. Compared with the global penetration rate of 4.7% of transcatheter aortic valve replacement, there is still much room for improvement
With the increase of the number of operations, the improvement of doctors' surgical skills, the improvement of patients' acceptance and the improvement of medical insurance coverage policies, the number of operations increased to expand the market scale and penetration; Meanwhile, compared with the global penetration rate of transcatheter aortic valve replacement (TAVR), there is still much room for improvement
With the rapid development of TMV technology in China and the increase of products submitted for approval in recent years, the capital continues to increase and occupy a place in the track, and well-known institutions at home and abroad such as Hillhouse capital and Sequoia Capital have joined the game one after another
Depp medical, Hanyu medical and newpulse medical are favored by Chinese and foreign capital; In May 2021, Peijia medical was listed on the Hong Kong Stock Exchange and raised about US $300 million. Jingwei China and hilling capital, the two major institutional shareholders, hold 10.07% and 9.33% respectively, with a market value of more than 12.4 billion in recent days
